ArticleEnvironmental analysis, health and toxicology2025
Astaxanthin ameliorates necroptosis through bisphenol-A exposure by regulating brain RIPK1/FADD/RIPK3/MLKL pathway in adult male rats.
Article in Environmental analysis, health and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphenol A (BPA), a common endocrine-disrupting chemical, can cause oxidative damage, apoptosis, and necroptosis in various organs. However, the underlying mechanisms for BPA-induced neurotoxicity were not properly reported. Here, we have evaluated the possible ameliorative roles of astaxanthin (ASX) against BPA-induced brain apoptosis/necroptosis in male rats. Forty male rats were equally grouped (30 days) into control, ASX (75 mg/kg), BPA (50 mg/kg), and BPA/ASX (50 mg/kg/BAP+75 mg/kg/ASX). The present findings demonstrated that ASX could mitigate the diminished acetylcholinesterase (AchE) activity and the increased dopamine, serotonin, and norepinephrine levels, besides anxiety behaviors that resulted from BPA intoxication. Furthermore, ASX significantly reduced BPA-induced brain oxidative injury by mitigating malondialdehyde (MDA), glutathione (GSH), glutathione transferase (GST), superoxide dismutase (SOD), and catalase (CAT) levels. Moreover, ASX could alleviate the histopathological changes promoted by BPA and repair the transcript levels of p53, BcL2, caspase9, FADD, RIPK1/3, MLKL along with Bax, and caspase3 immunoreactivity. In conclusion, ASX reserved brain injury-induced apoptosis, and necroptosis following exposure to BPA through p53/Bcl2/Bax/caspase9/capasase3 and RIPK1/FADD/RIPK3/MLKL pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.